Investors & Media Company Overview UNITY Biotechnology is developing therapeutics to slow, halt or reverse diseases of aging. UNITY's initial focus is on creating medicines that target cellular senescence and aging-related biology in ophthalmologic and neurologic diseases, while leveraging partnerships in growth areas with high unmet need. Stock Information Data Provided by Refinitiv. Minimum 15 minutes delayed. Latest Presentation Download News Releases October 6, 2021 UNITY Biotechnology Reports Granting of New Employment Inducement Awards October 5, 2021 UNITY Biotechnology Announces Positive 12-Week Data from Phase 1 Clinical Trial of UBX1325 in Advanced Vascular Eye Disease
October 5, 2021 UNITY Biotechnology Announces Positive 12-Week Data from Phase 1 Clinical Trial of UBX1325 in Advanced Vascular Eye Disease
